サンプル依頼リスト カート
  • English
  • Korean
表紙：虚血性脳卒中治療の世界市場 - 2023年～2030年
市場調査レポート
商品コード
1374884

虚血性脳卒中治療の世界市場 - 2023年～2030年

Global Ischemic stroke Treatment Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 194 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
虚血性脳卒中治療の世界市場 - 2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 194 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

虚血性脳卒中は、脳の領域への血液供給が遮断または減少し、脳組織が酸素と栄養を得ることができなくなったときに発症します。脳細胞は数分で死滅し始める。脳卒中は医学的危機であり、早急な治療が必要です。早すぎる処置は、脳の損傷やさらなる複雑な症状を軽減することができます。

虚血性脳卒中の主な治療法は、組織プラスミノーゲン活性化因子（tPA）と呼ばれる薬剤です。これは脳への血流を阻害する血栓を破壊します。ヘルスケアプロバイダーが腕の静脈にtPAを注射します。脳梗塞の症状が現れてから3時間以内に投与すれば、非常に有効です。

市場力学：市場促進要因と市場抑制要因

有病率の増加

脳卒中や動脈瘤の発生件数の増加は、今後数年間の世界市場の成長を促進すると予想されます。世界脳卒中機構の統計によると、脳卒中はすでに流行の兆しを見せており、25歳以上の成人の4人に1人が一生のうちに脳卒中を経験すると予想されています。今年、世界で1,220万人以上が初めて脳卒中に直面し、650万人が脳卒中で命を落とすと推定されています。

また、脳動脈瘤は英国では約3.0％の人が罹患しており、脳動脈瘤財団は毎年600万人以上の米国人が脳動脈瘤の影響を受けていると報告しています。さらに、認知度の向上や研究活動なども、予測期間中の世界市場の成長に寄与すると予想されます。

置換基の有効性

しかし、血栓回収デバイスの特許切れや参入は、予測期間中の世界市場成長を阻害する要因のひとつです。さらに、承認された治療法の不足や専門家の不足も、世界市場の成長を妨げる追加要因のひとつです。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 普及の拡大
    • 抑制要因
      • 置換基の入手可能性
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 償還分析
  • 特許分析
  • パイプライン分析
  • 疫学分析
  • SWOT分析
  • DMIオピニオン

第6章 COVID-19分析

第7章 薬剤クラス別

  • 組織プラスミノーゲン活性化薬（TPA）
  • 抗凝固薬
  • 抗血小板薬
  • スタチン
  • 抗高血圧薬
  • その他

第8章 投与経路別

  • 経口
  • 非経口

第9章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他のアジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Hoffmann-La Roche
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Pfizer
  • Bristol-Myers Squibb, Inc.
  • Boehringer Ingelheim GmbH
  • Sanofi
  • Daiichi Sankyo
  • AstraZeneca, Inc.
  • Amgen Inc.
  • Biogen Inc.
  • Merck and Co. Inc.

第13章 付録

目次
Product Code: PH7210

Overview

An ischemic stroke emerges when the blood supply to region of the brain is interrupted or decreased, stopping brain tissue from obtaining oxygen and nutrients. Brain cells start to die in minutes. A stroke is a medical crisis, and immediate attention is necessary. Premature action can lessen brain injury and additional intricacies.

The primary treatment for an ischemic stroke is a drug called tissue plasminogen activator (tPA). It busts up the blood clots that obstruct blood flow to the brain. A healthcare provider injects tPA into a vein in the arm. The drug is highly beneficial if given within 3 hours post-stroke manifestations begin.

Market Dynamics: Drivers & Restraints

Growing Prevalence

The rising events of brain stroke and aneurysms are expected to drive the growth of the global market in the coming years. As per the statistics provided by the World Stroke Organization, stroke has already reached epidemic proportions, with one out of four adults above the age of 25 expected to experience a stroke in their lifetime. It is estimated that over 12.2 million individuals worldwide will face their first stroke this year, and 6.5 million will succumb to it.

Additionally, brain aneurysm affects approximately 3.0% of people in the U.K., and the Brain Aneurysm Foundation has reported that more than 6.0 million Americans are affected by brain aneurysms every year. Furthermore, growing awareness and research activites among other factors are also expected to contribute to the global market growth during the forecast period.

Avaliability of Substituents

However, patent expiry and entry of Clot-retrieval devices are among the factors that may impede the global market growth during the forecast period. Furthermore, the lack of approved treatments available and professionals are among the additional factors hampering the global market growth.

Segment Analysis

The global ischemic stroke treatment market is segmented based on drug class, route of administration, distribution channel and region.

Tissue Plasminogen Activator Drug Class is Expected to Dominate Market

Tissue plasminogen activator is an efficacious blood thinner and is authorized for the therapy of stroke. It enhances the probability of recovery. A number of investigations observed that individuals who receive tissue plasminogen activator during their ischemic stroke have additional potential to recover totally or have more infrequent possibilities of disability than those who do not consume the medicine. Therefore, for all patients with ischemic stroke, a tissue plasminogen activator is a first-line therapy to treat, boosting the segment growth.

Moreover, in January 2022, Thrombolytic Science, LLC was awarded a second patent by the United States Patent and Trademark Office for the innovative therapy of ischemic stroke via the usage of fibrinolytic enzymes, tissue plasminogen activator, tPA, and urokinase plasminogen activator, uPA. The recent patent authorization is expected to pave the path for the evolution of tissue plasminogen activator-based treatment of stroke.

Geographical Analysis

North America is Expected to Dominate the Global Market

It is expected that the North American market will dominate the global market for stroke and aneurysm treatment due to the increasing prevalence of these conditions in the region. According to the Centers for Disease Control and Prevention, over 795,000 individuals in the United States experience a stroke each year, with approximately 610,000 of these being first or new strokes.

Shockingly, there is an estimated one stroke every 40 seconds in the United States and every four minutes, someone dies from a stroke. Stroke cases are mainly of the ischemic type, accounting for around 87% of all strokes, which occur when blood flow to the brain is blocked. Additionally, about 1 in 50 people in the United States have an unruptured brain aneurysm, which translates to approximately 6.7 million individuals. The yearly rate of rupture is estimated to be around 8-10 per 100,000 individuals.

COVID-19 Impact Analysis

Due to the COVID-19 pandemic, elective and routine medical visits and examinations were postponed or discontinued to redirect resources toward providing emergent care for critically ill patients and to prevent the spread of the virus. Healthcare workers were stretched thin, leading to increased turnover rates among full-time and contract workers, which put a strain on the system and reduced the capacity to deliver clinical assistance, negatively impacting the market.

Market Segmentation

By Drug Class

  • Tissue Plasminogen Activators (TPA)
  • Anticoagulants
  • Antiplatelets
  • Statins
  • Antihypertensives
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In September 2023, Sun Pharmaceutical Industrie's wholly-owned associate unit collaborated with US-based Pharmazz Inc to commercialise a drug utilized to treat cerebral ischemic stroke in India.
  • In February 2023, the US Food and Drug Administration (FDA) has allocated a move ahead letter for Pharmazz's investigational new drug (IND) application to initiate a Phase III clinical trial of Sovateltide (PMZ-1620) in acute cerebral ischaemic stroke patients.

Competitive Landscape

The major global players in the market include: Hoffmann-La Roche, Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, Sanofi, Daiichi Sankyo, AstraZeneca, Amgen Inc., Merck and Co. Inc. and Biogen Inc. among others.

Why Purchase the Report?

  • To visualize the global ischemic stroke treatment market segmentation based on drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of ischemic stroke treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global ischemic stroke treatment market report would provide approximately 61 tables, 59 figures and 194 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Class
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Prevalence
    • 4.1.2. Restraints
      • 4.1.2.1. Availability of Substituents
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Patent Analysis
  • 5.7. Pipeline Analysis
  • 5.8. Epidemiology
  • 5.9. SWOT Analysis
  • 5.10. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class
  • 7.2. Tissue Plasminogen Activators (TPA)*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Anticoagulants
  • 7.4. Antiplatelets
  • 7.5. Statins
  • 7.6. Antihypertensives
  • 7.7. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Parenteral

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail pharmacies
  • 9.4. Online pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Hoffmann-La Roche*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Pfizer
  • 12.3. Bristol-Myers Squibb, Inc.
  • 12.4. Boehringer Ingelheim GmbH
  • 12.5. Sanofi
  • 12.6. Daiichi Sankyo
  • 12.7. AstraZeneca, Inc.
  • 12.8. Amgen Inc.
  • 12.9. Biogen Inc.
  • 12.10. Merck and Co. Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us